Artivion Inc. (AORT) shares surged 15.60% in pre-market trading on Friday following the company's impressive second-quarter 2025 results, raised full-year guidance, and a series of analyst price target increases. The medical device company, known for its innovative cardiac and vascular products, demonstrated robust growth across key segments and financial metrics.

Artivion reported Q2 2025 adjusted earnings of 8 cents per share, significantly beating analyst expectations of breakeven results. Revenue rose 15.3% year-over-year to $112.97 million, surpassing the Wall Street estimate of $107.96 million. The company's strong performance was driven by double-digit growth in both revenue and adjusted EBITDA, with total revenue reaching $113 million, representing a 14% constant currency growth year-over-year. Adjusted EBITDA grew an impressive 33% to $24.8 million.

In response to the strong results, Artivion raised its full-year 2025 revenue guidance to $435–$443 million, reflecting constant currency growth of 12–14%. The company also increased its adjusted EBITDA guidance to $86–$91 million, anticipating a 200 basis point margin expansion. The positive outlook was further bolstered by the successful U.S. launch of AMDS (Aortic Mechanical Dissection System) and continued strong performance in the On-X valve segment, which grew 24% year-over-year. Following these developments, several analysts raised their price targets for Artivion, including Needham (to $45 from $32), Stifel (to $40 from $36), and Oppenheimer (to $40 from $32), reflecting increased confidence in the company's growth trajectory and market position.